Myelodysplastic Syndromes (MDS)
Brian Shaffer, MD
Robert Hasserjian, MD
Luspatercept in the treatment of lower-risk myelodysplastic syndromes
Transforming growth factor growth factor: A substance made by the body that stimulates the bone marrow to produce blood cells.
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
For the majority of patients with lower-risk myelodysplastic syndrome (LR-MDS), one of the primary clinical goals is to alleviate the symptoms associated with the resultant cytopenias and to minimize the transfusion burden.
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes Myelodysplastic Syndromes:
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
Disease overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation.